Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind Euro- pean Cooperative Study Group trial. Br Heart J. 1992;67:122 8. 338. Thompson PL, Aylward PE, Federman J, et al; for the National Heart Foundation of Australia Coronary Thrombolysis Group. A randomized comparison of intravenous heparin with oral aspirin and dipyridamole 24 hours after recombinant tissue-type plasminogen activator for acute myocardial infarction. Circulation. 1991;83:1534 42. 339. Granger CB, Hirsch J, Califf RM, et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarc- tion: results from the GUSTO-I trial. Circulation. 1996;93:870 8. 340. Fox KAA, Antman EM, Montalescot G, et al. The impact of renal dys- function on outcomes in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol. 2007;49:2249 55. 341. Peters RJG, Joyner C, Bassand J-P, et al. The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a sub- group analysis of the OASIS-6 trial. Eur Heart J. 2008;29:324 31. 342. White H. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet. 2001;358:1855 63. 343. Vogt A, von Essen R, Tebbe U, et al. Impact of early perfusion status of the infarct-related artery on short-term mortality after thrombolysis for acute myocardial infarction: retrospective analysis of four German multicenter studies. J Am Coll Cardiol. 1993;21:1391 5. 344. Gibson CM, Murphy SA, Rizzo MJ, et al; Thrombolysis In Myocardial Infarction (TIMI) Study Group. Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Circulation. 1999;99:1945 50. 345. Gibson CM, Cannon CP, Murphy SA, et al. 